Advertisement
Screener

Merck & Co., Inc. (MRK) ROI

Merck & Co., Inc. ROI

Return on investment (ROI), also called return on invested capital, is the profit a company earns for every dollar of long-term capital from both lenders and shareholders, shown as a percentage. It is net income divided by long-term debt plus shareholder equity, and the table shows both amounts. Because debt is included in the base, ROI does not rise just because a company replaces equity with borrowing, which sets it apart from ROE. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Merck & Co., Inc. roi for fiscal 2025 was 17.95%, a 12.63% decline from fiscal 2024.
  • Merck & Co., Inc. roi for fiscal 2024 was 20.54%, a 3986.55% increase from fiscal 2023.
  • Merck & Co., Inc. roi for fiscal 2023 was 0.50%, a 97.35% decline from fiscal 2022.
  • Merck & Co., Inc. roi for fiscal 2022 was 18.98%, a 3.62% increase from fiscal 2021.
Available history
2012-12-31 to 2025-12-31
Data captured

Historical ROI

DateROINet income 12 monthNet income 3 monthDebt plus equity
2025-12-3117.95%$18.25B$2.96B$101.71B
2024-12-3120.54%$17.12B$3.74B$83.33B
2023-12-310.50%$365M-$1.23B$72.62B
2022-12-3118.98%$14.52B$3.02B$76.5B
2021-12-3118.32%$13.05B$3.05B$71.25B
2020-12-3113.32%$7.07B-$2.09B$53.06B
2019-12-3119.44%$9.84B$2.36B$50.64B
2017-12-314.06%$2.4B-$1.05B$58.92B
2016-12-316.04%$3.92B-$595.00M$64.88B
2015-12-316.27%$4.44B$977.00M$70.9B
2014-12-3117.40%$11.92B$7.32B$68.49B
2013-12-315.87%$4.4B$781.00M$74.97B
2012-12-318.39%$6.17B$907.00M$73.52B

Annual ROI

DateROINet income 12 monthDebt plus equity
2025-12-3117.95%$18.25B$101.71B
2024-12-3120.54%$17.12B$83.33B
2023-12-310.50%$365M$72.62B
2022-12-3118.98%$14.52B$76.5B
2021-12-3118.32%$13.05B$71.25B
2020-12-3113.32%$7.07B$53.06B
2019-12-3119.44%$9.84B$50.64B
2017-12-314.06%$2.39B$58.92B
2016-12-316.04%$3.92B$64.88B
2015-12-316.27%$4.44B$70.9B
2014-12-3117.40%$11.92B$68.49B
2013-12-315.87%$4.4B$74.97B
2012-12-318.39%$6.17B$73.52B

Similar stocks

Stock NameCountryMarket CapPE Ratio
AbbVie Inc. (ABBV)United States$468.180B70.37
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60